Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ADC Therapeutics (ADCT) Revenue (2019 - 2026)

ADC Therapeutics has reported Revenue over the past 8 years, most recently at $20.0 million for Q1 2026.

  • Quarterly results put Revenue at $20.0 million for Q1 2026, up 300.66% from a year ago — trailing twelve months through Mar 2026 was $59.6 million (up 2.62% YoY), and the annual figure for FY2022 was $209908.0, down 99.31%.
  • Revenue reached $20.0 million in Q1 2026 per ADCT's latest filing, up from $15.8 million in the prior quarter.
  • Across five years, Revenue topped out at $69.8 billion in Q4 2022 and bottomed at $5.0 million in Q1 2025.
  • Median Revenue over the past 5 years was $18.4 million (2024), compared with a mean of $5.0 billion.
  • The largest annual shift saw Revenue skyrocketed 410334997.0% in 2022 before it crashed 81.01% in 2023.
  • Over 5 years, Revenue stood at $69.8 billion in 2022, then crashed by 99.98% to $14.5 million in 2023, then rose by 24.31% to $18.0 million in 2024, then fell by 12.58% to $15.8 million in 2025, then rose by 27.19% to $20.0 million in 2026.
  • Business Quant data shows Revenue for ADCT at $20.0 million in Q1 2026, $15.8 million in Q3 2025, and $18.8 million in Q2 2025.